



Flexion Therapeutics, Inc.
Investor Relations Department
10 Mall Road
Suite 301
Burlington, MA 01803
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FLXN

| | |
|---------------|----------------------------|
| Last Trade: | 23.71 |
| Trade Time: | 4:00 PM ET Aug 23, 2017 |
| Change: | 0.82 (+3.582%) |
| Day Range | 22.63 - 23.98 |
| 52-Week Range | 15.44 - 29.41 |
| Volume | 519,806 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late stage development for moderate to severe osteoarthritis pain.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 8, 2017
[Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights](#)

Aug 1, 2017
[Flexion Therapeutics to Report Second-Quarter 2017 Financial Results on August 8, 2017](#)

Jul 10, 2017
[Flexion Therapeutics to Hold Investor & Analyst Day Today](#)

Jul 3, 2017
[Flexion Therapeutics to Hold Investor and Analyst Day on July 10, 2017](#)

Jun 28, 2017
[Flexion Therapeutics Announces Appointment of Mark Levine as General Counsel](#)

Upcoming Events [\[View all \]](#)

Sep 6, 2017 9:40 AM ET
[2017 Wells Fargo Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 10, 2017
[Annual Report \(10-K\)](#)

Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 8, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)

Nov 7, 2016
[Quarterly Report \(10-Q\)](#)